VSTM Projected Dividend Yield
Verastem Inc ( NASDAQ : VSTM )Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors. 20 YEAR PERFORMANCE RESULTS |
VSTM Dividend History Detail VSTM Dividend News VSTM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |